DOREMY Study
Research type
Research Study
Full title
Dose Reduction of pre-operative radiotherapy in myxoid liposarcomas
IRAS ID
137155
Contact name
Aisha Miah
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Research summary
Summary of Research
Myxoid liposarcomas are a rare histological subtype of soft tissue sarcomas. Commonly a curative strategy for this disease is surgery and radiotherapy. This type of sarcoma is very sensitive to radiotherapy. From clinical experience when radiotherapy is delivered before surgery, a very large proportion of the tumour demonstrated response to radiotherapy by showing large volumes of necrosis (defined as a therapeutic effect). Because this is a very radiosensitive tumour, this study is asking the question whether a lower dose of radiation can achive the same effect. Consequently this could result in a lower incidence of early and late side effects from radiotherapy.
Summary of Results
The findings of the DOREMY non-randomized clinical trial suggest that deintensification of preoperative radiotherapy dose is effective and oncologically safe and is associated with less morbidity than historical controls, although differences in radiotherapy techniques and follow-up should be considered. A 36-Gy dose delivered in once-daily 2-Gy fractions is proposed as a dose-fractionation approach for myxoid liposarcoma, given that phase 3 trials are logistically impossible to execute in rare cancers.
REC name
Wales REC 6
REC reference
14/WA/1090
Date of REC Opinion
24 Sep 2014
REC opinion
Further Information Favourable Opinion